文献速递哮喘

规律比索洛尔对哮喘患者沙丁胺醇反应的影响:双盲随机安慰剂对照交叉试验

The impact of regular bisoprolol on the response to salbutamol in asthma: A double-blind randomized placebo-controlled crossover trial.
PubMed 文献 · Respirology · 2020-10-11

该双盲随机安慰剂对照交叉试验纳入19例轻度哮喘且甘露醇激发阳性的成人,比较每日比索洛尔(至5 mg,2周)与安慰剂后沙丁胺醇的支气管扩张反应。比索洛尔组沙丁胺醇AUC较安慰剂组平均低5%(单侧95%CI下限低26%),未超过预设30%的非劣效界值,提示规律使用心脏选择性β1受体阻滞剂比索洛尔不劣于安慰剂。

要点

  • 轻度哮喘患者规律使用比索洛尔至5 mg每日,沙丁胺醇支气管扩张反应非劣于安慰剂。
  • 开放扩展至10 mg每日的13例中,比索洛尔组AUC平均高11%(95%CI下限低5%)。
  • 研究支持心脏选择性β1受体阻滞剂在哮喘中并非绝对禁用,但需个体化评估。

核心结论

  • 在轻度哮喘成人中,规律使用心脏选择性β1受体阻滞剂比索洛尔后,甘露醇诱导支气管收缩后的沙丁胺醇支气管扩张反应不劣于安慰剂。

研究设计与样本

  • 随机顺序、双盲、安慰剂对照、非劣效交叉试验,比较每日比索洛尔至5 mg(2周)与匹配安慰剂,并设开放标签扩展至每日10 mg。
  • 共19例轻度哮喘且吸入甘露醇激发试验阳性的成人完成研究;13例完成开放标签扩展。

主要发现

  • 调整甘露醇所致FEV1下降和治疗顺序后,比索洛尔组沙丁胺醇AUC反应较安慰剂组平均低5%,单侧95%CI为低26%。
  • 开放标签扩展至每日10 mg比索洛尔后,平均AUC较安慰剂高11%,95%CI为低5%。

关键数值与推荐

  • 非劣效界值设定为AUC降低30%,基于既往研究。
  • 甘露醇激发以FEV1下降15%为支气管收缩标准。
  • 沙丁胺醇经储雾罐按5分钟间隔给予100、100和200 μg,重复测量FEV1。

临床怎么用

  • 对于需要心脏选择性β1受体阻滞剂的哮喘患者,规律使用比索洛尔至5 mg每日可能不影响急救沙丁胺醇的支气管扩张反应。
  • 临床决策仍需结合患者哮喘控制状态和个体反应,不能外推至所有哮喘人群。

局限性

  • 样本量较小(19例完成核心研究,13例完成开放扩展)。
  • 研究对象为轻度哮喘且甘露醇激发阳性,结果不能直接推广至中重度哮喘或未筛选人群。
  • 开放标签扩展部分非盲法,可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Non-selective beta-blockers impair the bronchodilator response to beta2 -agonists. Cardio-selective beta1 -blockers are less likely to cause this effect, yet they remain relatively contraindicated in asthma. We investigated whether the response to salbutamol is impaired during cardio-selective beta1 -blocker treatment in people with asthma. METHODS: A random-order, double-blind, placebo-controlled, non-inferiority, crossover study was conducted comparing up to 5 mg bisoprolol daily for 2 weeks with matching placebo, with an open-label extension of up to 10 mg bisoprolol daily. After each treatment period, mannitol was inhaled to induce bronchoconstriction with a 15% fall in forced expiratory volume in 1 s (FEV1 ). Immediately after mannitol challenge, salbutamol (100, 100 and 200 μg) was administered via spacer at 5-min intervals with repeated FEV1 measures. The FEV1 recovery with salbutamol was measured as an area under recovery curve (AUC). Based on earlier research, a clinically relevant non-inferiority limit of a 30% reduction in the AUC was set. RESULTS: A total of 19 adults with mild asthma and positive inhaled mannitol challenge completed the study. Adjusting for the FEV1 fall induced by mannitol and treatment sequence, the mean AUC response to salbutamol after bisoprolol was 5% lower than after placebo, with a one-sided 95% confidence interval (CI) of 26% lower. Thirteen participants completed the open-label extension up to 10 mg bisoprolol daily with mean AUC 11% higher after bisoprolol with a 95% CI of 5% lower. CONCLUSION: The bronchodilator response to rescue salbutamol after mannitol-induced bronchoconstriction is non-inferior during regular treatment with the cardio-selective beta1 -blocker, bisoprolol, compared to placebo. CLINICAL TRIAL REGISTRATION: ACTRN12618000306213 at https://www.anzctr.org.au.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Bennett MR, Chang CL, Tuffery C, et al. The impact of regular bisoprolol on the response to salbutamol in asthma: A double-blind randomized placebo-controlled crossover trial. Respirology. 2020. PMID: 33043552. doi:10.1111/resp.13955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。